The Globe and Mail reports in its Wednesday edition that Leede Jones Gable analyst Douglas Loe began coverage on Theratechnologies with a "speculative buy" rating. The Globe's David Leeder writes that Mr. Loe calls the company an "innovative HIV drug developer." He targets the shares at $4, $1.90 under the consensus. Mr. Loe says in a note: "Theratechnologies is a diversified pharma firm, with two specialty drugs Egrifta and Trogarzo already approved and targeting niche HIV indications with substantial quarterly revenue already being generated, if a bit below our original expectations for both drugs. Egrifta is a stabilized, fatty-acid-derivatized analog of growth hormone-releasing factor that has documented impact on reducing visceral adipose tissue deposition in HIV1-infected individuals. Trogarzo is a partnered anti-CD4 mAb that targets CD4-positive/HIV1-infected T-cells and mitigates HIV1 infection in patients that are no longer responsive to two or more of the small-molecule anti-retroviral drugs that are conventionally used to treat disease. Pivotal Phase III data were positive and FDA approval-enabling, and both drugs are projected to contribute positively to revenue/EBITDA throughout our forecast period."